{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '7', 'SELECTION OF PATIENTS', '7.1', 'INCLUSION CRITERIA', 'I 01. MVA and/or persistent stable angina despite angiographically successful PCI male or', 'female patients with:', 'A) Male and female patients not at childbearing potential >18 year-old or legal age of', 'majority.', 'B) Female patient if she has undergone sterilization at least 3 months earlier or is', 'postmenopausal.', '-', 'Post-menopausal status is defined by having no menses for 12 months without an', 'alternative medical cause,', '-', 'In females not treated with HRT, menopausal status is confirmed by a high follicle', 'stimulating hormone (FSH) level greater than 40 IU/L,', '-', 'In females on HRT and whose menopausal status is in doubt (ie, in women aged less', 'than 45 years), a highly effective contraception methods will be required.', 'Contraception should be used during the whole study and for at least seven days', 'corresponding to time needed to eliminate study treatment.', 'C) Symptomatic stable angina pectoris (typical or atypical symptoms with an average of at', 'least bi-weekly episodes over the past month).', 'D) Patients with non-obstructive (<50% stenosis) coronary arteries or intermediate stenosis', '(between 50 and 70%) should have FFR >0.80 or iFR >0.89 on angiogram, documented', 'within the previous 24 months*. In patients with stenting, a minimum diameter stenosis of', '<10% is required.', 'or', 'Coronary computed tomography angiography with finding of non-obstructive coronary', 'arteries within the past 24 months* in patients without previous PCI.', '*Note: in cases of clinically suspected progression of atherosclerosis as per the', 'Investigator, a more contemporary (i.e., 6 months) evidence should be provided.', 'or', 'CCTA performed during screening period, with finding of non-obstructive coronary', 'arteries, in patients diagnosed with MVA and stable angina without previous PCI who did', 'not have a coronary angiogram or CCTA in the previous 24 months but between 24', 'months to 5 years', 'E) Baseline global CFR (measured during the study) assessed by 13N-ammonia or 82Rubidium', 'PET scan <2.0.', 'I 02.', 'Signed written informed consent.', 'I 03.', 'Not under any administrative or legal supervision.', 'Property of the Sanofi Group - strictly confidential', 'Page 39', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '7.2', 'EXCLUSION CRITERIA', 'Patients who have met all the above inclusion criteria listed in Section 7.1 will be screened for the', 'following exclusion criteria which are sorted and numbered in the following 4 subsections:', '7.2.1 Exclusion criteria related to study methodology', 'E', '01. Any patient who, in the judgment of the Investigator, is likely to be noncompliant during', 'the study, or unable to cooperate because of a language problem or poor mental', 'development, or cannot be contacted in case of emergency.', 'E', '02. Patient who has taken other investigational drugs or SAR407899 for this study within', '3 months or 5 half-lives from screening or randomization, whichever is longer.', 'E 03. Any use of nitrates (except short-acting nitrates) and/or dipyridamole and/or PDE 5', 'inhibitors within one week prior to baseline PET scan or anticipated to be used during the', 'study.', 'E 04. Conditions/situations such as:', 'Patients with a short life expectancy (including heart failure New York Heart Association', '[NYHA] III or IV).', 'Presence or history of drug hypersensitivity that in the opinion of the investigator would', \"compromise patient' safety.\", 'Any history or presence of clinically relevant pulmonary, gastrointestinal, hepatic, renal,', 'metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic,', 'ocular, gynecologic (if female), or infectious disease, or signs of acute illness that', \"according to Investigator's judgment, would adversely affect the patient's participation in\", 'the study.', 'E 05. Esophageal dysmotility or esophagitis.', 'E 06. Patients with acute coronary syndrome (ACS) (MI and/or unstable angina) in previous', '3 months.', 'E 07. Unsuccessful or incomplete coronary revascularization with residual obstructive stenosis', 'or coronary artery disease progression in native vessels as documented on invasive', 'coronary angiography (50% stenosis) within 24 months of enrollment.', 'E 08. Percutaneous coronary intervention performed at the time of an ACS (MI or unstable', 'angina) in the previous 12 months.', 'E 09. Recent PCI within the past 3 months.', 'E 10. Patients with history of coronary artery bypass grafting (CABG).', 'E 11.', 'Recent (<3 months) major surgery (ie, valvular surgery, surgery for congenital heart', 'disease), stroke, TIA, sustained ventricular arrhythmia, clinically significant structural', 'heart disease (moderate-severe valvular disease, hypertrophic cardiomyopathy, congenital', 'heart disease, pulmonary hypertension).', 'Property of the Sanofi Group - strictly confidential', 'Page 40', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}